What is the recommended starting dose of venlafaxine (immediate‑release and extended‑release) in adults without renal or hepatic impairment, and how should it be adjusted for elderly or frail patients?

Starting Dose for Venlafaxine

For adults without renal or hepatic impairment, start venlafaxine immediate-release at 75 mg/day divided into 2-3 doses with food, or venlafaxine extended-release at 75 mg once daily. 1

Standard Adult Dosing

The FDA-approved starting dose is clearly established:

• Immediate-release (IR): 75 mg/day in 2-3 divided doses with food 1
• Extended-release (XR/ER): 75 mg once daily 2

After the initial dose, you can increase by 75 mg/day increments at intervals of no less than 4 days based on tolerability and clinical response 1. The typical therapeutic range is 75-225 mg/day for outpatients, though severely depressed inpatients may require up to 375 mg/day maximum 1.

Elderly and Frail Patients

No formal dose reduction is required based on age alone 1. However, the FDA label explicitly states that "caution should be exercised in treating the elderly" and "extra care should be taken when increasing the dose" 1.

Despite the lack of mandatory dose adjustment, clinical guidelines recommend a more conservative approach:

• Start at approximately 50% of the standard adult dose (i.e., 37.5 mg/day) in elderly patients 3
• This reflects the significantly greater risk of adverse drug reactions in older populations 3
• Research confirms elderly patients tolerate venlafaxine well at standard doses, but orthostatic hypotension occurs in 20% of older adults, increasing fall risk 4

Key Monitoring Points in Elderly Patients:

• Blood pressure: Both hypertension (6.5% incidence) and orthostatic hypotension (20% incidence) can occur, particularly at doses ≥225 mg/day 4
• Falls risk: New-onset orthostatic hypotension significantly increases fall probability 4
• Titrate more slowly and monitor standing/sitting BP regularly

Special Population Adjustments

Renal Impairment:

• Mild-moderate (GFR 10-70 mL/min): Reduce total daily dose by 25% 1
• Hemodialysis: Reduce total daily dose by 50% 1

Hepatic Impairment:

• Mild-moderate: Reduce total daily dose by 50% 1
• Individual variability is high; some patients may require >50% reduction 1

Formulation Considerations

Extended-release formulations offer advantages over immediate-release:

• Once-daily dosing improves adherence 2
• Lower nausea incidence: Nausea peaks in first 2 weeks then decreases 2
• Research shows XR demonstrated superiority over IR at week 12 on all efficacy measures 2

Common Pitfalls to Avoid

1. Don't start too high in elderly patients: While no mandatory reduction exists, starting at 37.5 mg/day is safer given orthostatic hypotension risk
2. Don't increase too quickly: Wait at least 4 days between dose increases 1
3. Don't ignore BP monitoring: Check both sitting and standing BP, especially at doses ≥225 mg/day 4
4. Don't assume age alone requires dose reduction: Base adjustments on renal/hepatic function and tolerability, not chronological age 1